Posted by SLS on September 20, 2006, at 21:49:06
In reply to Re: What does this mean? Behavioral sensitization., posted by zeugma on September 20, 2006, at 17:11:07
It's about time you showed up, Z.
I came across a paper for you to take a look at a few months back. I posted looking for you, but you were absent. Let me see if I can find it again.
Got it.
Have a good day.
- Scott-------------------------------------------
Sleep Med. 2001 Jan;2(1):63-65. Related Articles, Links
Click here to read
Narcolepsy and obesity: remission of severe cataplexy with sibutramine.Krahn LE, Moore WR, Altchuler SI.
Mayo Sleep Disorders Center, Mayo Clinic and Foundation, 200 First Street, SW, MN 55905, Rochester, USA
An overweight patient (body mass index of 34 kg/m(2)) with narcolepsy associated with cataplexy is described. Polysomnography did not indicate obstructive sleep apnea. Her obesity was treated with sibutramine, a norepinephrine, serotonin and dopamine reuptake inhibiting medication and her severe cataplexy remitted. Clinicians must be aware that sibutramine may suppress cataplexy when evaluating excessive daytime sleepiness in an overweight patient taking this anti-obesity medication. Therefore a negative history of cataplexy in these cases may be misleading and narcolepsy may be overlooked in the differential diagnosis. Sibutramine should be discontinued before polysomnography and multiple sleep latency testing but may be a useful medication in the management of obese narcoleptic patients with cataplexy. With the discovery of decreased hypocretin 1 levels in humans with narcolepsy, a neuropeptide that modulates sleep and feeding, the association between narcolepsy and obesity requires more attention.
PMID: 11152984 [PubMed - as supplied by publisher]
poster:SLS
thread:687712
URL: http://www.dr-bob.org/babble/20060919/msgs/687782.html